SEC Comment Letter 0000000000-25-003233 to Tenaya Therapeutics, Inc. (TNYA)
Tenaya Therapeutics, Inc.
Date: March 26, 2025 · CIK: 0001858848 · Accession: 0000000000-25-003233
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286005
Letter
Re: Tenaya Therapeutics, Inc. Registration Statement on Form S-3 Filed March 21, 2025 File No. 333-286005 Dear Faraz Ali:
March 26, 2025
Faraz Ali Chief Executive Officer Tenaya Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 500 South San Francisco, CA 94080
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jennifer Knapp
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 26, 2025 Faraz Ali Chief Executive Officer Tenaya Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 500 South San Francisco, CA 94080 Re: Tenaya Therapeutics, Inc. Registration Statement on Form S-3 Filed March 21, 2025 File No. 333-286005 Dear Faraz Ali: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer Knapp </TEXT> </DOCUMENT>